CTRI/2019/08/020770已完成2 期
Will methotrexate iontophoresis have fewer side effects compared to oral methotrexate in treatment of palmoplantar hyperkeratotic eczema?
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- SELF
- 入组人数
- 99
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients of age 18-60 years and consenting for the study.
- •Patients having palmoplantar hyperkeratotic eczema predominantly, having lesions of duration more than 8 weeks.
排除标准
- •Non consenting patient.
- •Pregnant and lactating females
- •Patient with hematological, renal, hepatic disorder and having malignancy.
- •Patient those on pacemakers ,cardiac arrhythmias, metallic implanted devices in the area current flows or intrauterine metallic implantations .
- •Hypersensitivity to previous methotrexate.
- •Patient who are on other immunosuppresive agent.
- •Patient who had been on systemic or topical steroids for >2 months.
- •Patients of palmoplantar hyperkeratotic eczema with proven allergen will be excluded.
研究者
相似试验
尚未招募
Unknown
Comparing methotrexate and methotrexate with methotrexate with apremilast in modifying biochemical parameters of psoriasis patients.CTRI/2023/03/050882Anisha Biswal
进行中（未招募）
1 期
Impact of concomitant Methotrexate on efficacy, safety and adherence of Ustekinumab-treatment in patients with active Psoriatic Arthritis (MUST-Study)active psoriatic arthritisMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2015-005777-20-DEFraunhofer Gesellschaft for its Institute Fraunhofer Institute for Translational Medicine and Pharmacology ITMP196
进行中（未招募）
不适用
EFFET DU METHOTREXATE SUR LA RELATION DOSE - EFFET DE L'INFLIXIMAB DANS LA SPONDYLARTHRITE ANKYLOSANTE - SPAXIMEUCTR2006-005157-29-FRCHRU-TOURS
尚未招募
4 期
Comparison of the effectiveness of two medicines namely Methotrexate and Apremilast in patients with a skin disease called psoriasisCTRI/2019/04/018854Yenepoya Medical College
进行中（未招募）
不适用
Etude de l'efficacité du méthotrexate en adjonction d'un anti-histaminique H1 dans le traitement de l'urticaire chronique idiopathique sévère réfractaire aux anti-H1 seuls : essai randomisé. - MUCISurticaire chronique idiopathique sévèreMedDRA version: 12.1Level: LLTClassification code 10009159Term: Chronic urticariaEUCTR2010-018716-33-FRCHRU de TOURS